HRP20050833A2 - Pyrroloimidazole derivatives, their preparation, pharmaceutical composition containing them, and their use as nootropic agents - Google Patents
Pyrroloimidazole derivatives, their preparation, pharmaceutical composition containing them, and their use as nootropic agents Download PDFInfo
- Publication number
- HRP20050833A2 HRP20050833A2 HR20050833A HRP20050833A HRP20050833A2 HR P20050833 A2 HRP20050833 A2 HR P20050833A2 HR 20050833 A HR20050833 A HR 20050833A HR P20050833 A HRP20050833 A HR P20050833A HR P20050833 A2 HRP20050833 A2 HR P20050833A2
- Authority
- HR
- Croatia
- Prior art keywords
- pyrrolo
- imidazole
- dione
- tetrahydro
- phenyl
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 239000008194 pharmaceutical composition Substances 0.000 title abstract description 3
- 239000002664 nootropic agent Substances 0.000 title description 4
- MHOZZUICEDXVGD-UHFFFAOYSA-N pyrrolo[2,3-d]imidazole Chemical class C1=NC2=CC=NC2=N1 MHOZZUICEDXVGD-UHFFFAOYSA-N 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 29
- 208000002193 Pain Diseases 0.000 claims abstract description 10
- 230000003070 anti-hyperalgesia Effects 0.000 claims abstract description 9
- 230000001777 nootropic effect Effects 0.000 claims abstract description 8
- 230000036407 pain Effects 0.000 claims abstract description 6
- 230000000202 analgesic effect Effects 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 122
- 125000000217 alkyl group Chemical group 0.000 claims description 25
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- 239000001257 hydrogen Substances 0.000 claims description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 16
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 230000008569 process Effects 0.000 claims description 15
- 238000006243 chemical reaction Methods 0.000 claims description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical group [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 13
- 125000003118 aryl group Chemical group 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 208000024827 Alzheimer disease Diseases 0.000 claims description 10
- 206010012289 Dementia Diseases 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 239000000725 suspension Substances 0.000 claims description 10
- 150000002431 hydrogen Chemical class 0.000 claims description 9
- 239000013598 vector Substances 0.000 claims description 9
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 8
- 239000012453 solvate Substances 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- -1 hydroxy, thio, amino, carboxyl Chemical group 0.000 claims description 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 7
- 208000004296 neuralgia Diseases 0.000 claims description 7
- 208000021722 neuropathic pain Diseases 0.000 claims description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 206010065390 Inflammatory pain Diseases 0.000 claims description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 6
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000006239 protecting group Chemical group 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- VSCBATMPTLKTOV-UHFFFAOYSA-N 2-tert-butylimino-n,n-diethyl-1,3-dimethyl-1,3,2$l^{5}-diazaphosphinan-2-amine Chemical compound CCN(CC)P1(=NC(C)(C)C)N(C)CCCN1C VSCBATMPTLKTOV-UHFFFAOYSA-N 0.000 claims description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 5
- 206010039966 Senile dementia Diseases 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 238000007363 ring formation reaction Methods 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 201000006474 Brain Ischemia Diseases 0.000 claims description 4
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 4
- 208000000094 Chronic Pain Diseases 0.000 claims description 4
- 208000019022 Mood disease Diseases 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 125000002837 carbocyclic group Chemical group 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 206010008118 cerebral infarction Diseases 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 206010015037 epilepsy Diseases 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 230000000968 intestinal effect Effects 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 239000003586 protic polar solvent Substances 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 230000002792 vascular Effects 0.000 claims description 4
- QRWIBQDPXGDRCZ-UHFFFAOYSA-N 1-(2-methylphenyl)-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazole-2,5-dione Chemical compound CC1=CC=CC=C1N1C(=O)CN2C(=O)CCC21 QRWIBQDPXGDRCZ-UHFFFAOYSA-N 0.000 claims description 3
- VFNQLOPSYQVHTO-UHFFFAOYSA-N 1-[(4-methylphenyl)methyl]-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazole-2,5-dione Chemical compound C1=CC(C)=CC=C1CN1C(=O)CN2C(=O)CCC21 VFNQLOPSYQVHTO-UHFFFAOYSA-N 0.000 claims description 3
- DGYLCNVWDTVZNK-UHFFFAOYSA-N 1-benzyl-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazole-2,5-dione Chemical compound O=C1CN(C(CC2)=O)C2N1CC1=CC=CC=C1 DGYLCNVWDTVZNK-UHFFFAOYSA-N 0.000 claims description 3
- DZRZZQCSSLBPTD-UHFFFAOYSA-N 1-phenyl-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazole-2,5-dione Chemical compound O=C1CCC2N1CC(=O)N2C1=CC=CC=C1 DZRZZQCSSLBPTD-UHFFFAOYSA-N 0.000 claims description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims description 3
- 206010047700 Vomiting Diseases 0.000 claims description 3
- 239000000010 aprotic solvent Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 150000001879 copper Chemical class 0.000 claims description 3
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 238000007327 hydrogenolysis reaction Methods 0.000 claims description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 3
- 230000000324 neuroprotective effect Effects 0.000 claims description 3
- 230000008673 vomiting Effects 0.000 claims description 3
- QRWIBQDPXGDRCZ-LLVKDONJSA-N (7ar)-1-(2-methylphenyl)-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazole-2,5-dione Chemical compound CC1=CC=CC=C1N1C(=O)CN2C(=O)CC[C@H]21 QRWIBQDPXGDRCZ-LLVKDONJSA-N 0.000 claims description 2
- QRWIBQDPXGDRCZ-NSHDSACASA-N (7as)-1-(2-methylphenyl)-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazole-2,5-dione Chemical compound CC1=CC=CC=C1N1C(=O)CN2C(=O)CC[C@@H]21 QRWIBQDPXGDRCZ-NSHDSACASA-N 0.000 claims description 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 2
- ZEABXXATIREXQL-UHFFFAOYSA-N 1-(2,6-dimethylphenyl)-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazole-2,5-dione Chemical compound CC1=CC=CC(C)=C1N1C(=O)CN2C(=O)CCC21 ZEABXXATIREXQL-UHFFFAOYSA-N 0.000 claims description 2
- WQEBXNDEOFIRLU-UHFFFAOYSA-N 1-(3,4-dimethylphenyl)-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazole-2,5-dione Chemical compound C1=C(C)C(C)=CC=C1N1C(=O)CN2C(=O)CCC21 WQEBXNDEOFIRLU-UHFFFAOYSA-N 0.000 claims description 2
- LABZIGIWAKWBCG-UHFFFAOYSA-N 1-(3,5-dimethylphenyl)-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazole-2,5-dione Chemical compound CC1=CC(C)=CC(N2C(CN3C(=O)CCC32)=O)=C1 LABZIGIWAKWBCG-UHFFFAOYSA-N 0.000 claims description 2
- ZARXCMOFEDRLIL-UHFFFAOYSA-N 1-(3-chlorophenyl)-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazole-2,5-dione Chemical compound ClC1=CC=CC(N2C(CN3C(=O)CCC32)=O)=C1 ZARXCMOFEDRLIL-UHFFFAOYSA-N 0.000 claims description 2
- XZHCKLIHYLQKQX-UHFFFAOYSA-N 1-(3-fluoro-2-methylphenyl)-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazole-2,5-dione Chemical compound CC1=C(F)C=CC=C1N1C(=O)CN2C(=O)CCC21 XZHCKLIHYLQKQX-UHFFFAOYSA-N 0.000 claims description 2
- VEPWRENTSYQEGN-UHFFFAOYSA-N 1-(3-fluoro-4-methylphenyl)-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazole-2,5-dione Chemical compound C1=C(F)C(C)=CC=C1N1C(=O)CN2C(=O)CCC21 VEPWRENTSYQEGN-UHFFFAOYSA-N 0.000 claims description 2
- JAUCLMKHGDLSKL-UHFFFAOYSA-N 1-(3-fluoro-5-methylphenyl)-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazole-2,5-dione Chemical compound CC1=CC(F)=CC(N2C(CN3C(=O)CCC32)=O)=C1 JAUCLMKHGDLSKL-UHFFFAOYSA-N 0.000 claims description 2
- LIYIVZXYOBXSHU-UHFFFAOYSA-N 1-(3-fluorophenyl)-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazole-2,5-dione Chemical compound FC1=CC=CC(N2C(CN3C(=O)CCC32)=O)=C1 LIYIVZXYOBXSHU-UHFFFAOYSA-N 0.000 claims description 2
- HTJGVYWGDFKHDJ-UHFFFAOYSA-N 1-(3-hydroxyphenyl)-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazole-2,5-dione Chemical compound OC1=CC=CC(N2C(CN3C(=O)CCC32)=O)=C1 HTJGVYWGDFKHDJ-UHFFFAOYSA-N 0.000 claims description 2
- BGIHCBMLWPBGHA-UHFFFAOYSA-N 1-(3-methoxyphenyl)-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazole-2,5-dione Chemical compound COC1=CC=CC(N2C(CN3C(=O)CCC32)=O)=C1 BGIHCBMLWPBGHA-UHFFFAOYSA-N 0.000 claims description 2
- DAXNQKQFRJRQKR-UHFFFAOYSA-N 1-(3-methylphenyl)-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazole-2,5-dione Chemical compound CC1=CC=CC(N2C(CN3C(=O)CCC32)=O)=C1 DAXNQKQFRJRQKR-UHFFFAOYSA-N 0.000 claims description 2
- MNTLLIAHJWUSOX-UHFFFAOYSA-N 1-(3-propan-2-ylphenyl)-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazole-2,5-dione Chemical compound CC(C)C1=CC=CC(N2C(CN3C(=O)CCC32)=O)=C1 MNTLLIAHJWUSOX-UHFFFAOYSA-N 0.000 claims description 2
- DUEICGOKWYPYJF-UHFFFAOYSA-N 1-(4-chloro-2-methylphenyl)-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazole-2,5-dione Chemical compound CC1=CC(Cl)=CC=C1N1C(=O)CN2C(=O)CCC21 DUEICGOKWYPYJF-UHFFFAOYSA-N 0.000 claims description 2
- MAAJXDAKIMDIRX-UHFFFAOYSA-N 1-(4-chloro-3-methylphenyl)-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazole-2,5-dione Chemical compound C1=C(Cl)C(C)=CC(N2C(CN3C(=O)CCC32)=O)=C1 MAAJXDAKIMDIRX-UHFFFAOYSA-N 0.000 claims description 2
- OZRAQDRDDGKDLV-UHFFFAOYSA-N 1-(4-chlorophenyl)-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazole-2,5-dione Chemical compound C1=CC(Cl)=CC=C1N1C(=O)CN2C(=O)CCC21 OZRAQDRDDGKDLV-UHFFFAOYSA-N 0.000 claims description 2
- XSMLJFJCISDAFX-UHFFFAOYSA-N 1-(4-ethylphenyl)-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazole-2,5-dione Chemical compound C1=CC(CC)=CC=C1N1C(=O)CN2C(=O)CCC21 XSMLJFJCISDAFX-UHFFFAOYSA-N 0.000 claims description 2
- KAEJMYYSRRGNPK-UHFFFAOYSA-N 1-(4-fluorophenyl)-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazole-2,5-dione Chemical compound C1=CC(F)=CC=C1N1C(=O)CN2C(=O)CCC21 KAEJMYYSRRGNPK-UHFFFAOYSA-N 0.000 claims description 2
- IEEXZTRJOZFMNF-UHFFFAOYSA-N 1-(4-methoxyphenyl)-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazole-2,5-dione Chemical compound C1=CC(OC)=CC=C1N1C(=O)CN2C(=O)CCC21 IEEXZTRJOZFMNF-UHFFFAOYSA-N 0.000 claims description 2
- IABKCVSRMMSOMZ-UHFFFAOYSA-N 1-(4-methylphenyl)-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazole-2,5-dione Chemical compound C1=CC(C)=CC=C1N1C(=O)CN2C(=O)CCC21 IABKCVSRMMSOMZ-UHFFFAOYSA-N 0.000 claims description 2
- UEQLEBAXFRLMHS-UHFFFAOYSA-N 1-(4-methylsulfonylphenyl)-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazole-2,5-dione Chemical compound C1=CC(S(=O)(=O)C)=CC=C1N1C(=O)CN2C(=O)CCC21 UEQLEBAXFRLMHS-UHFFFAOYSA-N 0.000 claims description 2
- MELSJYIFDQJVGE-UHFFFAOYSA-N 1-(4-propan-2-ylphenyl)-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazole-2,5-dione Chemical compound C1=CC(C(C)C)=CC=C1N1C(=O)CN2C(=O)CCC21 MELSJYIFDQJVGE-UHFFFAOYSA-N 0.000 claims description 2
- VZCMMNMNGIPJGF-UHFFFAOYSA-N 1-(5-fluoro-2-methylphenyl)-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazole-2,5-dione Chemical compound CC1=CC=C(F)C=C1N1C(=O)CN2C(=O)CCC21 VZCMMNMNGIPJGF-UHFFFAOYSA-N 0.000 claims description 2
- CSQHNICETCRZIA-UHFFFAOYSA-N 1-(5-methylpyridin-2-yl)-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazole-2,5-dione Chemical compound N1=CC(C)=CC=C1N1C(=O)CN2C(=O)CCC21 CSQHNICETCRZIA-UHFFFAOYSA-N 0.000 claims description 2
- OOOYLKZJENWPCZ-UHFFFAOYSA-N 1-[2-(trifluoromethyl)phenyl]-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazole-2,5-dione Chemical compound FC(F)(F)C1=CC=CC=C1N1C(=O)CN2C(=O)CCC21 OOOYLKZJENWPCZ-UHFFFAOYSA-N 0.000 claims description 2
- IPKOYJIWZYYXDQ-UHFFFAOYSA-N 1-[3-(trifluoromethyl)phenyl]-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazole-2,5-dione Chemical compound FC(F)(F)C1=CC=CC(N2C(CN3C(=O)CCC32)=O)=C1 IPKOYJIWZYYXDQ-UHFFFAOYSA-N 0.000 claims description 2
- WTPLXKNGZPPXLT-UHFFFAOYSA-N 1-[4-(hydroxymethyl)phenyl]-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazole-2,5-dione Chemical compound C1=CC(CO)=CC=C1N1C(=O)CN2C(=O)CCC21 WTPLXKNGZPPXLT-UHFFFAOYSA-N 0.000 claims description 2
- GIKCNOACQMJSLA-UHFFFAOYSA-N 1-[4-(trifluoromethyl)phenyl]-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazole-2,5-dione Chemical compound C1=CC(C(F)(F)F)=CC=C1N1C(=O)CN2C(=O)CCC21 GIKCNOACQMJSLA-UHFFFAOYSA-N 0.000 claims description 2
- BHCHGAOLRKPAEI-UHFFFAOYSA-N 1-naphthalen-2-yl-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazole-2,5-dione Chemical compound C1=CC=CC2=CC(N3C(=O)CN4C3CCC4=O)=CC=C21 BHCHGAOLRKPAEI-UHFFFAOYSA-N 0.000 claims description 2
- XCYCDACRNJWRSL-UHFFFAOYSA-N 1-pyridin-2-yl-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazole-2,5-dione Chemical compound O=C1CCC2N1CC(=O)N2C1=CC=CC=N1 XCYCDACRNJWRSL-UHFFFAOYSA-N 0.000 claims description 2
- WJZQYHBHLNBQEA-UHFFFAOYSA-N 1-pyridin-3-yl-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazole-2,5-dione Chemical compound O=C1CCC2N1CC(=O)N2C1=CC=CN=C1 WJZQYHBHLNBQEA-UHFFFAOYSA-N 0.000 claims description 2
- BNMZMLNDHLVITH-UHFFFAOYSA-N 1-thiophen-2-yl-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazole-2,5-dione Chemical compound O=C1CCC2N1CC(=O)N2C1=CC=CS1 BNMZMLNDHLVITH-UHFFFAOYSA-N 0.000 claims description 2
- QYOKEBJFAMPWFE-UHFFFAOYSA-N 2-(2,5-dioxo-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazol-1-yl)benzonitrile Chemical compound O=C1CCC2N1CC(=O)N2C1=CC=CC=C1C#N QYOKEBJFAMPWFE-UHFFFAOYSA-N 0.000 claims description 2
- LFWPAWVVOFABCG-UHFFFAOYSA-N 3-(2,5-dioxo-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazol-1-yl)benzonitrile Chemical compound O=C1CCC2N1CC(=O)N2C1=CC=CC(C#N)=C1 LFWPAWVVOFABCG-UHFFFAOYSA-N 0.000 claims description 2
- OLRISRJSBPDOTD-UHFFFAOYSA-N 3-(2-methylpropyl)-1-phenyl-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazole-2,5-dione Chemical compound O=C1C(CC(C)C)N(C(CC2)=O)C2N1C1=CC=CC=C1 OLRISRJSBPDOTD-UHFFFAOYSA-N 0.000 claims description 2
- BEBSJPNIGPYASL-UHFFFAOYSA-N 3-benzyl-1-phenyl-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazole-2,5-dione Chemical compound O=C1CCC(N(C2=O)C=3C=CC=CC=3)N1C2CC1=CC=CC=C1 BEBSJPNIGPYASL-UHFFFAOYSA-N 0.000 claims description 2
- STVSKIWIWXZOFJ-UHFFFAOYSA-N 3-methyl-1-phenyl-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazole-2,5-dione Chemical compound O=C1C(C)N(C(CC2)=O)C2N1C1=CC=CC=C1 STVSKIWIWXZOFJ-UHFFFAOYSA-N 0.000 claims description 2
- WVRRVSRIMRBZAQ-UHFFFAOYSA-N 4-(2,5-dioxo-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazol-1-yl)benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N1C(=O)CN2C(=O)CCC21 WVRRVSRIMRBZAQ-UHFFFAOYSA-N 0.000 claims description 2
- ZABQMYDNGNNLIT-UHFFFAOYSA-N 4-(2,5-dioxo-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazol-1-yl)benzonitrile Chemical compound O=C1CCC2N1CC(=O)N2C1=CC=C(C#N)C=C1 ZABQMYDNGNNLIT-UHFFFAOYSA-N 0.000 claims description 2
- LPLDTTQBKJRREB-UHFFFAOYSA-N 7a-methyl-1-phenyl-6,7-dihydro-3h-pyrrolo[1,2-a]imidazole-2,5-dione Chemical compound CC12CCC(=O)N1CC(=O)N2C1=CC=CC=C1 LPLDTTQBKJRREB-UHFFFAOYSA-N 0.000 claims description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical group CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 2
- 229910006074 SO2NH2 Inorganic materials 0.000 claims description 2
- 230000003474 anti-emetic effect Effects 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 230000003197 catalytic effect Effects 0.000 claims description 2
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical group I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 2
- QAILLXQUJOBHQV-UHFFFAOYSA-N ethyl 4-(2,5-dioxo-3,6,7,7a-tetrahydropyrrolo[1,2-a]imidazol-1-yl)benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1N1C(=O)CN2C(=O)CCC21 QAILLXQUJOBHQV-UHFFFAOYSA-N 0.000 claims description 2
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 2
- 150000007529 inorganic bases Chemical class 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 150000007530 organic bases Chemical class 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000000565 sulfonamide group Chemical group 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000008096 xylene Substances 0.000 claims description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 2
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 1
- 150000001649 bromium compounds Chemical group 0.000 claims 1
- 238000009833 condensation Methods 0.000 claims 1
- 230000005494 condensation Effects 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical group I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003094 microcapsule Substances 0.000 claims 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 abstract description 3
- 230000002490 cerebral effect Effects 0.000 abstract description 2
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 8
- XTXXOHPHLNROBN-UHFFFAOYSA-N dimiracetam Chemical compound N1C(=O)CN2C1CCC2=O XTXXOHPHLNROBN-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000007832 Na2SO4 Substances 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- NGHTXZCKLWZPGK-UHFFFAOYSA-N nefiracetam Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1C(=O)CCC1 NGHTXZCKLWZPGK-UHFFFAOYSA-N 0.000 description 5
- 229950004663 nefiracetam Drugs 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- IHLAQQPQKRMGSS-UHFFFAOYSA-N oxiracetam Chemical compound NC(=O)CN1CC(O)CC1=O IHLAQQPQKRMGSS-UHFFFAOYSA-N 0.000 description 4
- AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 3
- 208000000114 Pain Threshold Diseases 0.000 description 3
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical group NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 230000003920 cognitive function Effects 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 229960001227 oxiracetam Drugs 0.000 description 3
- 230000037040 pain threshold Effects 0.000 description 3
- 235000015320 potassium carbonate Nutrition 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 210000003497 sciatic nerve Anatomy 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000011593 sulfur Chemical group 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000004454 Hyperalgesia Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 150000001502 aryl halides Chemical class 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 201000005518 mononeuropathy Diseases 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- 229910052757 nitrogen Chemical group 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 description 1
- WZRKSPFYXUXINF-UHFFFAOYSA-N 1-(bromomethyl)-4-methylbenzene Chemical compound CC1=CC=C(CBr)C=C1 WZRKSPFYXUXINF-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- QSSXJPIWXQTSIX-UHFFFAOYSA-N 1-bromo-2-methylbenzene Chemical compound CC1=CC=CC=C1Br QSSXJPIWXQTSIX-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- VSPSRRBIXFUMOU-UHFFFAOYSA-N 2-amino-4-methylpentanamide;hydrochloride Chemical compound Cl.CC(C)CC(N)C(N)=O VSPSRRBIXFUMOU-UHFFFAOYSA-N 0.000 description 1
- MFYVYJSUTRYPOS-UHFFFAOYSA-N 3-(2-methylpropyl)-3,6,7,7a-tetrahydro-1h-pyrrolo[1,2-a]imidazole-2,5-dione Chemical compound N1C(=O)C(CC(C)C)N2C1CCC2=O MFYVYJSUTRYPOS-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 229940121683 Acetylcholine receptor antagonist Drugs 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- HPHUVLMMVZITSG-UHFFFAOYSA-N Etiracetam Chemical compound CCC(C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 238000006639 Goldberg reaction Methods 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 238000006254 arylation reaction Methods 0.000 description 1
- YCOXTKKNXUZSKD-UHFFFAOYSA-N as-o-xylenol Natural products CC1=CC=C(O)C=C1C YCOXTKKNXUZSKD-UHFFFAOYSA-N 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229950002911 dimiracetam Drugs 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- QFMPHCGACBODIJ-UHFFFAOYSA-N ethyl 4-oxobutanoate Chemical compound CCOC(=O)CCC=O QFMPHCGACBODIJ-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 description 1
- SNHMUERNLJLMHN-UHFFFAOYSA-N iodobenzene Chemical compound IC1=CC=CC=C1 SNHMUERNLJLMHN-UHFFFAOYSA-N 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 description 1
- 229960004002 levetiracetam Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- IMYZQPCYWPFTAG-IQJOONFLSA-N mecamylamine Chemical compound C1C[C@@H]2C(C)(C)[C@@](NC)(C)[C@H]1C2 IMYZQPCYWPFTAG-IQJOONFLSA-N 0.000 description 1
- 229960002525 mecamylamine Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000007074 memory dysfunction Effects 0.000 description 1
- 125000006431 methyl cyclopropyl group Chemical group 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004973 motor coordination Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- IJRRWXRFNKOLPQ-UHFFFAOYSA-N n-(2,5-dimethylphenyl)-2-(2-oxopyrrolidin-1-yl)acetamide Chemical compound CC1=CC=C(C)C(NC(=O)CN2C(CCC2)=O)=C1 IJRRWXRFNKOLPQ-UHFFFAOYSA-N 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000011302 passive avoidance test Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229960004526 piracetam Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010825 rotarod performance test Methods 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000101 thioether group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000573A ITMI20030573A1 (it) | 2003-03-24 | 2003-03-24 | Composti ad azione nootropica, loro preparazione, |
| PCT/EP2004/050339 WO2004085438A2 (en) | 2003-03-24 | 2004-03-22 | Pyrroloimidazole derivatives, their preparation, pharmaceutical composition containing them, and their use as nootropic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20050833A2 true HRP20050833A2 (en) | 2006-02-28 |
Family
ID=33042696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20050833A HRP20050833A2 (en) | 2003-03-24 | 2005-09-22 | Pyrroloimidazole derivatives, their preparation, pharmaceutical composition containing them, and their use as nootropic agents |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US7544705B2 (pt) |
| EP (1) | EP1608655B8 (pt) |
| JP (1) | JP4920408B2 (pt) |
| CN (1) | CN100522963C (pt) |
| AT (1) | ATE401327T1 (pt) |
| AU (1) | AU2004224087B2 (pt) |
| BR (1) | BRPI0408601A (pt) |
| CA (1) | CA2520008C (pt) |
| CY (1) | CY1108401T1 (pt) |
| DE (1) | DE602004015089D1 (pt) |
| DK (1) | DK1608655T3 (pt) |
| EA (1) | EA009558B1 (pt) |
| ES (1) | ES2309534T3 (pt) |
| HK (1) | HK1083837A1 (pt) |
| HR (1) | HRP20050833A2 (pt) |
| IT (1) | ITMI20030573A1 (pt) |
| NO (1) | NO20054898L (pt) |
| NZ (1) | NZ543154A (pt) |
| PL (2) | PL1608655T3 (pt) |
| PT (1) | PT1608655E (pt) |
| RS (1) | RS20050725A (pt) |
| SI (1) | SI1608655T1 (pt) |
| WO (1) | WO2004085438A2 (pt) |
| ZA (1) | ZA200508578B (pt) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20030573A1 (it) * | 2003-03-24 | 2004-09-25 | Nikem Research Srl | Composti ad azione nootropica, loro preparazione, |
| EP1925304A1 (en) * | 2006-11-15 | 2008-05-28 | Nikem Research S.R.L. | Pyrrolo[1,2-a]imidazoledione effective in the treatment of peripheral neurotoxicity induced by chemotherapeutic agents |
| ITMI20070770A1 (it) | 2007-04-16 | 2008-10-17 | Brane Discovery S R L | Impiego di dimiracetam nel trattamento del dolore cronico |
| AU2012201853B2 (en) * | 2007-04-16 | 2013-06-27 | Neurotune Ag | Use of dimiracetam in the treatment of chronic pain |
| CN107243007A (zh) | 2008-10-16 | 2017-10-13 | 约翰斯.霍普金斯大学 | 改善认知功能的方法和组合物 |
| US9125898B2 (en) | 2008-11-14 | 2015-09-08 | Neurotune Ag | Acetam derivatives for pain relief |
| BR112012019923A2 (pt) * | 2010-02-09 | 2016-08-09 | Univ Johns Hopkins | métodos e composições para melhorar a função cognitiva |
| KR101896349B1 (ko) * | 2010-07-26 | 2018-09-07 | 노이로툰 아게 | 디미라세탐의 제조 방법 |
| CA2891122C (en) | 2012-11-14 | 2021-07-20 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| EP2968220B1 (en) | 2013-03-15 | 2021-05-05 | Agenebio, Inc. | Methods and compositions for improving cognitive function |
| WO2014144663A1 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| CN107810002B (zh) | 2015-05-22 | 2021-01-05 | 艾吉因生物股份有限公司 | 左乙拉西坦的延时释放药物组合物 |
| JOP20190251A1 (ar) | 2017-05-31 | 2019-10-21 | Metys Pharmaceuticals AG | تركيبات تآزرية تشتمل على (r)-ديميراسيتام (1) و(s)-ديميراسيتام (2) بنسبة غير راسيمية |
| MX2021006243A (es) | 2018-12-04 | 2021-08-11 | Metys Pharmaceuticals AG | Composiciones sinergicas que comprenden (r)-2-(2-oxopirrolidin-1-i l)butanamida y (s)-2-(2-oxopirrolidin-1-il)butanamida en una proporcion no racemica. |
| WO2020115096A1 (en) | 2018-12-04 | 2020-06-11 | Metys Pharmaceuticals AG | Synergistic compositions comprising r-2-(substituted-sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2h)-ones and s-2-(substituted-sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2h)-ones in a non-racemic ratio |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4582838A (en) * | 1984-08-24 | 1986-04-15 | Warner-Lambert Company | Derivatives of dihydro-1H-pyrrolo[1,2-c]imidazol-3,5-dione as cognition activators |
| US5200406A (en) * | 1988-02-08 | 1993-04-06 | I.S.F. Societa Per Azioni | Pharmaceutically useful 2,5-dioxo-1H-octahydroimidazo[1,2-A]azepines |
| IT1233860B (it) * | 1988-02-08 | 1992-04-21 | Isf Spa | Derivati del peridroazacicloalca (1,2-a) imidazolo ad attivita' nootropa |
| JP3400466B2 (ja) * | 1991-10-28 | 2003-04-28 | 日本水産株式会社 | 高純度エイコサペンタエン酸またはそのエステルの製造方法 |
| GB9123641D0 (en) * | 1991-11-07 | 1992-01-02 | Isf Spa | Process |
| ITMI20030573A1 (it) * | 2003-03-24 | 2004-09-25 | Nikem Research Srl | Composti ad azione nootropica, loro preparazione, |
| EP1925304A1 (en) * | 2006-11-15 | 2008-05-28 | Nikem Research S.R.L. | Pyrrolo[1,2-a]imidazoledione effective in the treatment of peripheral neurotoxicity induced by chemotherapeutic agents |
-
2003
- 2003-03-24 IT IT000573A patent/ITMI20030573A1/it unknown
-
2004
- 2004-03-22 CA CA2520008A patent/CA2520008C/en not_active Expired - Fee Related
- 2004-03-22 CN CNB2004800055916A patent/CN100522963C/zh not_active Expired - Fee Related
- 2004-03-22 PL PL04741432T patent/PL1608655T3/pl unknown
- 2004-03-22 EA EA200501501A patent/EA009558B1/ru not_active IP Right Cessation
- 2004-03-22 DE DE602004015089T patent/DE602004015089D1/de not_active Expired - Lifetime
- 2004-03-22 WO PCT/EP2004/050339 patent/WO2004085438A2/en active IP Right Grant
- 2004-03-22 RS YUP-2005/0725A patent/RS20050725A/sr unknown
- 2004-03-22 PL PL378939A patent/PL378939A1/pl unknown
- 2004-03-22 ES ES04741432T patent/ES2309534T3/es not_active Expired - Lifetime
- 2004-03-22 JP JP2006505479A patent/JP4920408B2/ja not_active Expired - Fee Related
- 2004-03-22 EP EP04741432A patent/EP1608655B8/en not_active Expired - Lifetime
- 2004-03-22 SI SI200430868T patent/SI1608655T1/sl unknown
- 2004-03-22 AU AU2004224087A patent/AU2004224087B2/en not_active Ceased
- 2004-03-22 PT PT04741432T patent/PT1608655E/pt unknown
- 2004-03-22 US US10/550,483 patent/US7544705B2/en not_active Expired - Fee Related
- 2004-03-22 DK DK04741432T patent/DK1608655T3/da active
- 2004-03-22 AT AT04741432T patent/ATE401327T1/de not_active IP Right Cessation
- 2004-03-22 NZ NZ543154A patent/NZ543154A/en unknown
- 2004-03-22 BR BRPI0408601-5A patent/BRPI0408601A/pt not_active Application Discontinuation
-
2005
- 2005-09-22 HR HR20050833A patent/HRP20050833A2/hr not_active Application Discontinuation
- 2005-10-21 ZA ZA200508578A patent/ZA200508578B/en unknown
- 2005-10-24 NO NO20054898A patent/NO20054898L/no not_active Application Discontinuation
-
2006
- 2006-03-30 HK HK06103951A patent/HK1083837A1/xx not_active IP Right Cessation
-
2008
- 2008-10-08 CY CY20081101113T patent/CY1108401T1/el unknown
-
2009
- 2009-02-13 US US12/378,475 patent/US7732473B2/en not_active Expired - Fee Related
-
2010
- 2010-02-17 US US12/658,973 patent/US20100173945A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20050833A2 (en) | Pyrroloimidazole derivatives, their preparation, pharmaceutical composition containing them, and their use as nootropic agents | |
| US6583147B1 (en) | Pyrazolopyrimidinone derivatives for the treatment of impotence | |
| TWI801388B (zh) | 二氮雜雙環經取代之咪唑并嘧啶類及其用途 | |
| JP2008545739A5 (pt) | ||
| WO1998029397A1 (fr) | Composes pyrimidine a anneaux condenses et leur utilisation medicinale | |
| JP2005523338A (ja) | キナーゼ阻害剤として有用なピロロトリアジンアニリン化合物 | |
| WO2007015567A1 (ja) | 環状アミン化合物 | |
| EP0623621A1 (en) | Oxazabicyclo derivatives and their use as 5-HT4 receptor agonists | |
| JP2006516653A (ja) | キナーゼ阻害剤ピロロトリアジンの製造方法 | |
| JP2006525302A (ja) | ニコチン性アセチルコリン受容体の正のモジュレーター | |
| WO1998015552A1 (fr) | DERIVES DE 1H-PYRIDO[3,4-b]INDOLE-4-CARBOXAMIDE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE | |
| BG109767A (bg) | Пиридинови производни на алкил оксиндоли като 5-нт7 рецепторни активни агенти | |
| JPH11193289A (ja) | ピロールスルホンアミド誘導体 | |
| WO2008032764A1 (fr) | Dérivé hétérocyclique fusionné | |
| KR20070035046A (ko) | (1ｓ,5ｓ)-3-(5,6-디클로로-3-피리디닐)-3,6-디아자비사이클로[3.2.0]헵탄 | |
| FR2601951A1 (fr) | Nouvelles tetrahydrocarbazolones, composition pharmaceutique les contenant et leur procede de preparation | |
| MXPA05009903A (en) | Pyrroloimidazole derivatives, their preparation, pharmaceutical composition containing them, and their use as nootropic agents | |
| JP2941702B2 (ja) | ５‐ｈｔ３レセプターにおいて５‐ｈｔの作用に拮抗するラクタム誘導体を含む医薬組成物 | |
| WO2004080965A1 (ja) | ニューロペプチドff受容体拮抗剤 | |
| JP2000344775A (ja) | 新規化合物及び該化合物を含有する医薬組成物 | |
| JPH0665241A (ja) | 縮合イミダゾール化合物、その製造法及び剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| PPPP | Transfer of rights |
Owner name: BRANE DISCOVERY S.R.L., IN IN LIQUIDAZIONE, IT |
|
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20100320 Year of fee payment: 7 |
|
| OBST | Application withdrawn |